Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). Our aim was to assess the efficacy and safety of Tocilizumab (TCZ) in GO refractory to conventional therapy. This was an open-label multicenter study of glucocorticoid-resistant GO treated with TCZ. The...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Med
Prif Awduron: Sánchez-Bilbao, Lara, Martínez-López, David, Revenga, Marcelino, López-Vázquez, Ángel, Valls-Pascual, Elia, Atienza-Mateo, Belén, Valls-Espinosa, Beatriz, Maiz-Alonso, Olga, Blanco, Ana, Torre-Salaberri, Ignacio, Rodríguez-Méndez, Verónica, García-Aparicio, Ángel, Veroz-González, Raúl, Jovaní, Vega, Peiteado, Diana, Sánchez-Orgaz, Margarita, Tomero, Eva, Toyos-Sáenz de Miera, Francisco J., Pinillos, Valvanera, Aurrecoechea, Elena, Mora, Ángel, Conesa, Arantxa, Fernández-Prada, Manuel, Troyano, Juan A., Calvo-Río, Vanesa, Demetrio-Pablo, Rosalía, González-Mazón, Íñigo, Hernández, José L., Castañeda, Santos, González-Gay, Miguel Á., Blanco, Ricardo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563792/
https://ncbi.nlm.nih.gov/pubmed/32878150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092816
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg